Beijing Institute of Basic Medical Sciences, Beijing, China.
J Med Virol. 2021 Apr;93(4):1923-1925. doi: 10.1002/jmv.26769. Epub 2021 Jan 11.
SARS-CoV-2 nucleocapsid (N) protein has been proposed as a good vaccine target. N-specific T cells were observed in SARS-CoV-2 N immunized mice and COVID-19 convalescents. It is of importance to identify the T cell responses triggered by SARS-CoV-2 N protein. Intradermal immunization with SARS-CoV N protein was demonstrated to elicit non-protective T cell responses which may be avoided by intranasal vaccination. Therefore, we conducted intranasal vaccination of BALB/c mice with recombinant adenovirus type-5 expressing SARS-CoV-2 N protein. Such procedure induced CD8 T cell responses in the lung. Meanwhile CD4 T cell responses were observed in the spleen, which was associated with robust antibody production. Our study further supports the notion that SARS-CoV-2 N protein can work as a target for vaccine development.
严重急性呼吸综合征冠状病毒 2 核衣壳 (N) 蛋白已被提议作为一种良好的疫苗靶标。在 SARS-CoV-2 N 免疫的小鼠和 COVID-19 康复者中观察到了 N 特异性 T 细胞。重要的是要确定由 SARS-CoV-2 N 蛋白引发的 T 细胞反应。已证明用 SARS-CoV N 蛋白进行皮内免疫会引起非保护性 T 细胞反应,而鼻腔内接种可避免这种反应。因此,我们用表达 SARS-CoV-2 N 蛋白的重组腺病毒 5 型对 BALB/c 小鼠进行了鼻腔内接种。这种方法在肺部诱导了 CD8 T 细胞反应。同时在脾脏中观察到 CD4 T 细胞反应,这与强烈的抗体产生有关。我们的研究进一步支持了这样的观点,即 SARS-CoV-2 N 蛋白可以作为疫苗开发的靶标。